Slide 1: Business Highlights and 4Q and Full Year 2023 Financial Results Webcast
NASDAQ: KOD KODIAK.COM MEDICINES COMPANY Business Highlights and 4Q and Full Year 2023 Financial Results - Webcast March 28, 2024
Slide 2: Special Note Regarding Forward-Looking Statements
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS — These slides contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking st
Slide 3: The Ophthalmology Medicines Company
THE OPHTHALMOLOGY MEDICINES COMPANY OUR MISSION |] TRAILBLAZING 2 GENERATION 2.0 3 SINGULAR FOCUS IN SCIENCE MEDICINES OPHTHALMOLOGY Our creative and Our challenge to the Our 24/7/365 thoughtful foundation status quo KODIAK
Slide 4: A portfolio of clinical programs on the ABC Platform
A portfolio of 3 clinical programs: 2 are ABC Platform-derived and 1 is Platform- independent, with significant operational synergy and risk diversification Tarcocimab Anti-VEGF ABC ( Ww ¥ RY, KSI-501 Bispecific Anti-IL-6 Anti-VEGF ABC {formerly KSI-SOIABC) Antibody Biopolymer Conjugate (“ABC”) Plat
Slide 5: Program highlights and recent progress
3 positive Phase 3 studies: Diabetic Retinopathy (DR), Retinal Vein Occlusion (RVO) and wet AMD Strong and consistent 6-month durability signal and favorable safety across the pivotal program Regulatory alignment achieved on bridging strategy for go-to-market formulation Phase 3 study GLOW2 in DR no
Slide 6: Advancing tarcocimab toward BLA; accelerating KSI-501 and KSI-101
Advancing tarcocimab toward BLA with GLOW2; accelerating KSI-501 and KSI-101 development with rapid paths to Phase 3 value inflection points + Five Phase 3 studies planned for inclusion in BLA + Phase 1 study in DME met objectives + Phase 1b study enrollment submission; 3 completed and 2 in process
Slide 7: Tarcocimab
Tarcocimab Tedromer “ABC” VW, We believe tarcocimab can be a meaningfully differentiated product, and we intend to finish the clinical development of the program to enable marketing authorization application KODIAK ABC: antibody biopolymer conjugate; AMD: age-related macular degeneration
Slide 8: Plan to evaluate tarcocimab in two new Phase 3 studies
Plan to evaluate tarcocimab in two new Phase 3 studies, in DR and wet AMD, using the go-to- market formulation that improves manufacturability and may enhance utility + We believe tarcocimab can be an important medicine for patients and a meaningfully differentiated product in the marketplace * Go-t
Slide 9: GLOW2 features a similar design to GLOW1 with additional loading dose
GLOW2 features a similar study design as the successful GLOW1 study, with the benefit of an additional 34 monthly loading dose (Week O, 4, 8) Tarcocimab 5 m Basacts ane Dosing versus sem | imab _ Tarcocimasm9 | pay | me A BA mm (@}0/O el; AT eA B Tarcocimabinjection ‘ Y Y © Sham treatment 3 monthly
Slide 10: KSI-501
KSI-501 and bispecific “ABC” The KSI-501 program is the result of fine-tuning our ABC platform and Company, fast forwarding 10 years of design, manufacturing, clinical and operational expertise KODIAK ABC: antibody biopolymer conjugate; AMD: age-related macular degeneration; DR: diabetic retinopathy
Slide 11: Patient variability observed with anti-VEGF monotherapy
Substantial patient-to-patient variability is observed with anti-VEGF monotherapy, suggesting the need for additional mechanisms of action OCT CST change from baseline during year 1 for BCVA change from baseline during year 1 for pa \ wong ecu individual patients treated with Q8W aflibercept individ
Slide 12: "Two hands on the ball"
“Two hands on the ball” VEGF Trap KODIAK KSI-501 bispecific protein features unique design that enables highly efficient binding to both IL-6 and VEGF This first-in-class bispecific has the capability of inhibiting one VEGF dimer in addition to two IL-6 molecules, simultaneously The VEGF trap mimics
Slide 13: Phase 1 study of KSI-501 in diabetic macular edema
Phase 1 study of KSI-501 was a multiple ascending dose study in patients with diabetic macular edema PELE. DO W4 WS WIZ WIG W20 W24 Primary Endpoint: Ocular and systemic safety at Week 24 T T T T T 1 W4 W8 WIZ WIG W20 W24 T T 1 wa WI2 WI6 W20 W24 13mg fF f I 1 1 7 Do W&4 WS WI2 WIG W20 W24 Study Des
Slide 14: -50 0 -100 -150 -50 0 4 8 12 16 20 24 0 4
15 10 10 5 5 0 0 0 4 8 12 16 20 24 0 4 8 12 16 20 24 0 50 -50 0 -100 -150 -50 0 4 8 12 16 20 24 0 4 8 12 16 20 24 • •
Slide 15: Plan to advance KSI-501 into Phase 3 DAYBREAK study in wet AMD
Plan to advance KSI-501 into the Phase 3 DAYBREAK study in wet AMD in 2024 + Abundant preclinical evidence shows that IL-6 promotes choroidal neovascularization in animal models of wet AMD D A Y B R E A K * Clinical evidence demonstrates that IL-6 is associated with: * Development and progression of
Slide 16: KSI-101: First-in-class bispecific protein
KSI-1 Ol jst) First-in-class bispecific protein to address inflammation and vascular permeability concurrently Anti-IL-6 and VEGF trap * Inflammation is present in a wide spectrum of retinal bispecific protein diseases that lack intravitreal biologic options today a A new market segment separate fro
Slide 17: High unmet need for safer, disease modifying therapies
High unmet need for safer, disease modifying therapies. The opportunity is primed for safe and effective biologics to move up the treatment pathway towards first line therapy Current treatment algorithm for macular edema associated with inflammation IL Local or systemic corticosteroids * Mainstay of
Slide 18: Plan to initiate Phase 1b study in 2Q24; dual Phase 2b/3 studies planned
Plan to initiate a Phase 1b study in 2Q24; dual Phase 2b/3 pivotal studies planned for later in the year following regulatory alignment on study design ¢ Intend to start a dose-finding Phase 1b study in 2Q2024 to identify two dose levels to progress into pivotal studies * Currently in conversation w
Slide 19: Next steps
Tarcocimab tedromer + Phase 3 GLOW2 in DR nowrecruiting * Validating durability in Phase 3 DAYBREAK wet KODIAK SCIENCES AMD study * One successful clinical trial away from filing for N E XT registration ST E p S KSI-501 a * First-in-class, anti-IL-6 and anti-VEGF bispecific * $286 million in cash an